Skip to main content
. 2012 Dec 17;4(1):48–63. doi: 10.18632/oncotarget.756

Figure 8. MTHFD2 knockdown sensitizes breast cancer cells to methotrexate.

Figure 8

A: Western blot analysis of MTHFD2 and vimentin expression in response to 5μM methotrexate, monensin and salinomycin. B: Analysis of cell viability in response to MTHFD2 knockdown and treatment with 0.5 μM methotrexate, cisplatin and paclitaxel (***p < 0.005).